<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347344</url>
  </required_header>
  <id_info>
    <org_study_id>P160927J</org_study_id>
    <secondary_id>2017-001481-23</secondary_id>
    <nct_id>NCT03347344</nct_id>
  </id_info>
  <brief_title>Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)</brief_title>
  <acronym>ATRIL</acronym>
  <official_title>Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ATRIL is a multi-centric, double-blind randomized, two-arm controlled study. 42&#xD;
      SpinoCerebellar Ataxia type 2 (SCA2) patients, both gender, at least 18 years of age will be&#xD;
      included.&#xD;
&#xD;
      Riluzole 50 mg will be administered (per os) twice a day, versus one group with placebo for&#xD;
      12 months.&#xD;
&#xD;
      Riluzole (Rilutek®) is a benzothiazole drug, market approved, for Amyotrophic Lateral&#xD;
      Sclerosis (ALS). It delays the onset of ventilator-dependence or tracheostomy in selected&#xD;
      patients and may increase survival.&#xD;
&#xD;
      Scale for the Assessment and Rating of Ataxia (SARA) will be used at M0, M6 and M12. To&#xD;
      assess primary criterion, the percentage of patients with a decrease of at least 1 point of&#xD;
      the SARA score between the inclusion visit, and Visit 3 (Months 12) will be calculated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inherited cerebellar ataxias are genetically heterogeneous neurological disorders. They are&#xD;
      characterized by ataxic gait and cerebellar dysarthria that progresses over time with loss of&#xD;
      ambulation and speech. The mutations by expansions of CAG triplets in the genes ATXN1 (SCA1),&#xD;
      ATXN 2 (SCA2), 3 (SCA3), CACNA1A (SCA6), ATXN 7 (SCA7), and TBP (SCA17) are responsible for&#xD;
      50% of hereditary forms There is no curative or preventive treatment. This phase III study is&#xD;
      a multi-centric, double-blind randomized, two-arm controlled study (one group with 50 mg&#xD;
      Riluzole twice a day versus one group with placebo), to measure the efficacy of treatment&#xD;
      with riluzole in SCA2 patients during 12 months. Amelioration is defined by a 1 point&#xD;
      decrease of the SARA score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-centric, double-blind randomized, two-arm controlled study (one group with 50 mg riluzole twice a day versus one group with placebo), during one year</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Treatments will be presented in numbered boxes, labeled for this study according to the Good Manufacturing Practices by the General Agency of Equipment and Health Products (AGEPS).&#xD;
Each numbered box will consist of 6 months of treatment: 20 blister packs of 20 active or placebo tablets</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ataxia symptoms (Scale for the Assessment and Rating of Ataxia (SARA))</measure>
    <time_frame>at 12 months.</time_frame>
    <description>To compare the proportion of patients with Scale for the Assessment and Rating of Ataxia (SARA) improvement (decrease) of at least one point from baseline to 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Ataxia symptoms (Composite Cerebellar Functional Severity (CCFS) score)</measure>
    <time_frame>at 12 months</time_frame>
    <description>To compare the difference of the CCFS score (Composite Cerebellar Functional Severity Score) from baseline at 12 months. A decrease is expected in the intervention group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in extracerebellar symptoms (Inventory of Non-Ataxia Signs (INAS))</measure>
    <time_frame>at 12 months</time_frame>
    <description>To compare the difference of the extracerebellar symptoms (INAS, Inventory of Non-Ataxia Signs) by showing decrease in the INAS count from baseline at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 months survival</measure>
    <time_frame>at 12 months</time_frame>
    <description>To compare survival of the patients between the two treatment groups at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Spinocerebellar Ataxia Type 2</condition>
  <arm_group>
    <arm_group_label>RILUZOLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet. The tablets will be held under a blister of 20 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet matching the appearance of the Riluzole used in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>50 mg will be administered (per os) twice a day</description>
    <arm_group_label>RILUZOLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg will be administered (per os) twice a day</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetically diagnosed SCA2 (CAG triplet in ATXN2 ≥ 33)&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
          -  Covered by social security&#xD;
&#xD;
          -  SARA score ≥ 5 and ≤ 26&#xD;
&#xD;
          -  Age at onset ≤ 50 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treated with riluzole prior to the study&#xD;
&#xD;
          -  Hepatotoxic medication&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
          -  Serious systemic illnesses or conditions known for enhancing the side effects of&#xD;
             riluzole&#xD;
&#xD;
          -  Contraindications for MRI examination&#xD;
&#xD;
          -  Participation in another therapeutic trial (3 months exclusion period)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Non abstinence or absence of effective contraception for women&#xD;
&#xD;
          -  Inability to understand information about the protocol&#xD;
&#xD;
          -  Persons deprived of their liberty by judicial or administrative decision&#xD;
&#xD;
          -  Adult subject under legal protection or unable to consent&#xD;
&#xD;
          -  Other ataxic syndromes than SCA2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DURR Alexandra, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASSISTANCE PUBLIQUE HÖPITAUX DE PARIS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durr</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinocerebellar ataxia-SCA2</keyword>
  <keyword>SARA (Scale for the Assessment and Rating of Ataxia) score</keyword>
  <keyword>Riluzole (Rilutek)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

